BioCentury | Mar 22, 2010
Clinical News

Nasulin intranasal insulin: Preliminary Phase IIa data

...has rights to develop and market Nasulin in Africa, Asia and the Middle East, while Dong Sung...
...in South Korea. Biocon Ltd. (NSE:BIOCON; BSE:BIOCON), Bangalore, India CPEX Pharmaceuticals Inc. (NASDAQ:CPEX), Exeter, N.H. Dong Sung Pharmaceutical Co. Ltd....
BioCentury | Jan 4, 2010
Clinical News

Nasulin intranasal insulin: Completed Phase IIa enrollment

...has rights to develop and market Nasulin in Africa, Asia and the Middle East, while Dong Sung...
...in South Korea. Biocon Ltd. (NSE:BIOCON; BSE:BIOCON), Bangalore, India CPEX Pharmaceuticals Inc. (NASDAQ:CPEX), Exeter, N.H. Dong Sung Pharmaceutical Co. Ltd....
BioCentury | Mar 2, 2009
Clinical News

Nasulin intranasal insulin: Phase IIa started

...has rights to develop and market Nasulin in Asia, Africa and the Middle East, while Dong Sung...
...in South Korea. Biocon Ltd. (NSE:BIOCON; BSE:BIOCON), Bangalore, India CPEX Pharmaceuticals Inc. (NASDAQ:CPEX), Exeter, N.H. Dong Sung Pharmaceutical Co. Ltd....
BioCentury | Nov 17, 2008
Clinical News

Nasulin intranasal insulin: Phase I data

...has rights to develop and market Nasulin in Asia, Africa and the Middle East, while Dong Sung...
...in South Korea. Biocon Ltd. (NSE:BIOCON; BSE:BIOCON), Bangalore, India CPEX Pharmaceuticals Inc. (NASDAQ:CPEX), Exeter, N.H. Dong Sung Pharmaceutical Co. Ltd....
BioCentury | Sep 1, 2008
Company News

Generex, Dong Sung sales and marketing update

...and certain Asian countries, waived its Korean rights to allow for an exclusive license to Dong Sung...
...a global Phase III trial (see BioCentury, April 7). Generex Biotechnology Corp. (NASDAQ:GNBT), Toronto, Ontario Dong Sung Pharmaceutical Co. Ltd....
BioCentury | Feb 18, 2008
Clinical News

Nasulin intranasal insulin: Preliminary Phase II data

...holds rights to develop and market Nasulin in Asia, Africa and the Middle East, while Dong Sung...
...in South Korea. Bentley Pharmaceuticals Inc. (AMEX:BNT), Exeter, N.H. Biocon Ltd. (NSE:BIOCON; BSE:BIOCON), Bangalore, India Dong Sung Pharmaceutical Co. Ltd....
BioCentury | Jul 2, 2007
Clinical News

Nasulin intranasal insulin: Interim Phase II data

...holds rights to develop and market Nasulin in Asia, Africa and the Middle East, while Dong Sung...
...Humulin and Humalog. Bentley Pharmaceuticals Inc. (BNT), Exeter, N.H. Biocon Ltd. (NSE:BIOCON; BSE:BIOCON), Bangalore, India Dong Sung Pharmaceutical Co. Ltd....
BioCentury | Sep 12, 2005
Product Development

Insulin delivery landscape

...Nordisk AERx iDMS inhaled insulin Ph III (A) Generex Oral-lyn; Oralin (buccal) Ph IIb (B) Bentley/Dong Sung...
BioCentury | May 2, 2005
Company News

Bentley Pharma, Dong Sung Pharm. Co. Ltd. deal

...The companies partnered to develop BNT's intranasal insulin in South Korea to treat diabetes. Dong Sung will...
...Phase III trials and be responsible for regulatory submissions. Bentley Pharmaceuticals Inc. (BNT), Exeter, N.H. Dong Sung...
Items per page:
1 - 9 of 9
BioCentury | Mar 22, 2010
Clinical News

Nasulin intranasal insulin: Preliminary Phase IIa data

...has rights to develop and market Nasulin in Africa, Asia and the Middle East, while Dong Sung...
...in South Korea. Biocon Ltd. (NSE:BIOCON; BSE:BIOCON), Bangalore, India CPEX Pharmaceuticals Inc. (NASDAQ:CPEX), Exeter, N.H. Dong Sung Pharmaceutical Co. Ltd....
BioCentury | Jan 4, 2010
Clinical News

Nasulin intranasal insulin: Completed Phase IIa enrollment

...has rights to develop and market Nasulin in Africa, Asia and the Middle East, while Dong Sung...
...in South Korea. Biocon Ltd. (NSE:BIOCON; BSE:BIOCON), Bangalore, India CPEX Pharmaceuticals Inc. (NASDAQ:CPEX), Exeter, N.H. Dong Sung Pharmaceutical Co. Ltd....
BioCentury | Mar 2, 2009
Clinical News

Nasulin intranasal insulin: Phase IIa started

...has rights to develop and market Nasulin in Asia, Africa and the Middle East, while Dong Sung...
...in South Korea. Biocon Ltd. (NSE:BIOCON; BSE:BIOCON), Bangalore, India CPEX Pharmaceuticals Inc. (NASDAQ:CPEX), Exeter, N.H. Dong Sung Pharmaceutical Co. Ltd....
BioCentury | Nov 17, 2008
Clinical News

Nasulin intranasal insulin: Phase I data

...has rights to develop and market Nasulin in Asia, Africa and the Middle East, while Dong Sung...
...in South Korea. Biocon Ltd. (NSE:BIOCON; BSE:BIOCON), Bangalore, India CPEX Pharmaceuticals Inc. (NASDAQ:CPEX), Exeter, N.H. Dong Sung Pharmaceutical Co. Ltd....
BioCentury | Sep 1, 2008
Company News

Generex, Dong Sung sales and marketing update

...and certain Asian countries, waived its Korean rights to allow for an exclusive license to Dong Sung...
...a global Phase III trial (see BioCentury, April 7). Generex Biotechnology Corp. (NASDAQ:GNBT), Toronto, Ontario Dong Sung Pharmaceutical Co. Ltd....
BioCentury | Feb 18, 2008
Clinical News

Nasulin intranasal insulin: Preliminary Phase II data

...holds rights to develop and market Nasulin in Asia, Africa and the Middle East, while Dong Sung...
...in South Korea. Bentley Pharmaceuticals Inc. (AMEX:BNT), Exeter, N.H. Biocon Ltd. (NSE:BIOCON; BSE:BIOCON), Bangalore, India Dong Sung Pharmaceutical Co. Ltd....
BioCentury | Jul 2, 2007
Clinical News

Nasulin intranasal insulin: Interim Phase II data

...holds rights to develop and market Nasulin in Asia, Africa and the Middle East, while Dong Sung...
...Humulin and Humalog. Bentley Pharmaceuticals Inc. (BNT), Exeter, N.H. Biocon Ltd. (NSE:BIOCON; BSE:BIOCON), Bangalore, India Dong Sung Pharmaceutical Co. Ltd....
BioCentury | Sep 12, 2005
Product Development

Insulin delivery landscape

...Nordisk AERx iDMS inhaled insulin Ph III (A) Generex Oral-lyn; Oralin (buccal) Ph IIb (B) Bentley/Dong Sung...
BioCentury | May 2, 2005
Company News

Bentley Pharma, Dong Sung Pharm. Co. Ltd. deal

...The companies partnered to develop BNT's intranasal insulin in South Korea to treat diabetes. Dong Sung will...
...Phase III trials and be responsible for regulatory submissions. Bentley Pharmaceuticals Inc. (BNT), Exeter, N.H. Dong Sung...
Items per page:
1 - 9 of 9